1. Medtech Insight
  2. >>Business
  3. >>Strategy

St. Paul and the Foundry Team Up

Combining the resources and skills of an incubator and venture fund, with contacts in two of the most important medical device communities, Minneapolis-based St. Paul Ventures and West Coast-based The Foundry are joining forces.

Combining the resources and skills of an incubator and venture fund, with contacts in two of the most important medical device communities, Minneapolis-based St. Paul Ventures and West Coast-based The Foundry are joining forces, as St. Paul becomes an investor in The Foundry and Allan Will, founder of the incubator, joins the venture firm as a general partner. St. Paul recently raised a new $1 billion fund, of which one-quarter of the proceeds will go to health care, and 80% of its health care investments will be in medical devices.

For St. Paul partner David Stassen, the partnership with Will was a long time coming. Stassen, who joined St. Paul...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

European Hospital Products Sourced Through ‘System That Rewards Exploitation,’ Watchdog Finds

 
• By Shubham Singh

While European sustainability directives CSDDD and CSRD are still in the process of adoption, environmental group Swedwatch claims the EU's procurement framework is devoid of accountability.

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.